You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Access Language Arts
SBC: ATTAINMENT CO., INC. Topic: N/APurpose: Instruction in English Language Arts (ELA) for students with severe intellectual disabilities and autism can be challenging, as these students often do not have the skills to engage with text. In recent years, special education experts have proposed a comprehensive approach to supporting students with intellectual disabilities and autism in ELA, centered on strategies including word ident ...
SBIR Phase II 2014 Department of Education -
Antifungal Compound Discovery from Metagenomes
SBC: LUCIGEN CORPORATION Topic: NIAIDDESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Glycoengineered baculoviruses for the production of more efficacious influenza va
SBC: Glycobac, LLC Topic: NIAIDDESCRIPTION (provided by applicant): Vaccination significantly reduces morbidity and mortality caused by annual influenza epidemics. Traditionally, influenza vaccines have been manufactured using adapted influenza virus grown in eggs. However, this methodsuffers from inherent disadvantages such as slow production and allergenic egg proteins in the final product. To avoid these drawbacks, new vacci ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel system for sensitive detection of botulinum neurotoxins
SBC: ALPHA UNIVERSE LLC Topic: NIAIDDESCRIPTION (provided by applicant): The existence of terrorist organizations around the world, along with their ability to recruit expertise from physicians and scientists, poses an increasing threat of bioterrorist attack to society. In order to reduce the consequences of such an attack or even prevent it, new systems for detection of biothreat agents are necessary. Currently existing express ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of TAK1 Compounds for Neonatal Onset Multisystem Inflammatory Disease
SBC: CONFLUENCE LIFE SCIENCES, INC. Topic: NIAMSDESCRIPTION (provided by applicant): Cryopyrin-associated periodic syndromes (CAPS) are a family of rare autoinflammatory diseases of which neonatal-onset multisystem inflammatory disease (NOMID) is the most severe phenotype. NOMID is characterized by NLRP3 activating mutations resulting in excessive interleukin- 1?IL-1?and IL-18 production associated with recurrent fever, rash, skeletal lesions, ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
BAC Sudoku Sequencing Paradigm to Accelerate Metagenomic Natural Product Chemistr
SBC: LUCIGEN CORPORATION Topic: NCCIHDESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against microbial pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antimicrobial compounds with potentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Increased bioavailability of polyphenols through bacterial metabolism
SBC: AGRO BIOSCIENCES, INC. Topic: NCCIHDESCRIPTION (provided by applicant): Numerous preclinical studies have demonstrated multiple health benefits including anti- inflammatory, antioxidant, and chemopreventive effects of dietary polyphenols. These compounds are abundant in plants and have added to the health benefits of many fruits, such as raspberries, pomegranates, and strawberries. As aging population in the U.S. and other develope ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment
SBC: CENTROSE LLC Topic: NCIProject Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cases and 13,680 deaths will be attributed to renal cancerin the United States. Renal cancer is the most common malignancy of the adult kidney and accounts for 2-3% of all adult malignancies. Of these, 3 ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AAAPT Technology for Improving Chemotherapy
SBC: SCI-ENGI-MEDCO SOLUTIONS, INC Topic: NCIDESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Long acting injected liposomal buprenorphine for chronic pain/addiction in people
SBC: Plumb Pharmaceuticals LLC Topic: NIDADESCRIPTION: In this proposal, Comfort Care for Animals LLC (CCA) (Madison, WI) will create slow-release (minimum 10-12 days in this Phase, with an ultimate goal of 28 days) injectable liposomal buprenorphine formulation to treat moderate to severe post-surgical or chronic pain in people and animals and to use as a treatment for opioid addiction in people. This innovative new drug-delivery system ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health